Current Management of In-Stent Restenosis

被引:4
作者
Giacoppo, Daniele [1 ]
Mazzone, Placido Maria [1 ]
Capodanno, Davide [1 ]
机构
[1] Univ Catania, Dept Surg & Med Surg Specialties, Div Cardiol, Azienda Osped Univ Policlin Rodol San Marco, Via Santa Sofia 78, I-95124 Catania, Italy
关键词
in-stent restenosis; percutaneous coronary intervention; drug-coated balloon; drug-eluting stent; intravascular imaging; DRUG-ELUTING STENT; PACLITAXEL-COATED BALLOON; OPTICAL COHERENCE TOMOGRAPHY; DUAL-ANTIPLATELET THERAPY; PERCUTANEOUS CORONARY INTERVENTION; BIORESORBABLE VASCULAR SCAFFOLDS; RANDOMIZED-TRIAL; INTRAVASCULAR LITHOTRIPSY; CUTTING BALLOON; ARTERY-DISEASE;
D O I
10.3390/jcm13082377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
引用
收藏
页数:22
相关论文
共 136 条
  • [21] Byrne R., 2023, P EUROPCR 2023
  • [22] 2023 ESC Guidelines for the management of acute coronary syndromes
    Byrne, Robert A.
    Rossello, Xavier
    Coughlan, J. J.
    Barbato, Emanuele
    Berry, Colin
    Chieffo, Alaide
    Claeys, Marc J.
    Dan, Gheorghe-Andrei
    Dweck, Marc R.
    Galbraith, Mary
    Gilard, Martine
    Hinterbuchner, Lynne
    Jankowska, Ewa A.
    Juni, Peter
    Kimura, Takeshi
    Kunadian, Vijay
    Leosdottir, Margret
    Lorusso, Roberto
    Pedretti, Roberto F. E.
    Rigopoulos, Angelos G.
    Gimenez, Maria Rubini
    Thiele, Holger
    Vranckx, Pascal
    Wassmann, Sven
    Wenger, Nanette Kass
    Ibanez, Borja
    ESC Sci Document Grp
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (38) : 3720 - 3826
  • [23] Coronary balloon angioplasty, stents, and scaffolds
    Byrne, Robert A.
    Stone, Gregg W.
    Ormiston, John
    Kastrati, Adnan
    [J]. LANCET, 2017, 390 (10096) : 781 - 792
  • [24] Drug-coated balloon therapy in coronary and peripheral artery disease
    Byrne, Robert A.
    Joner, Michael
    Alfonso, Fernando
    Kastrati, Adnan
    [J]. NATURE REVIEWS CARDIOLOGY, 2014, 11 (01) : 13 - 23
  • [25] Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial
    Byrne, Robert A.
    Neumann, Franz-Josef
    Mehilli, Julinda
    Pinieck, Susanne
    Wolff, Britta
    Tiroch, Klaus
    Schulz, Stefanie
    Fusaro, Massimiliano
    Ott, Ilka
    Ibrahim, Tareq
    Hausleiter, Joerg
    Valina, Christian
    Pache, Juergen
    Laugwitz, Karl-Ludwig
    Massberg, Steffen
    Kastrati, Adnan
    [J]. LANCET, 2013, 381 (9865) : 461 - 467
  • [26] Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis A PRODIGY Trial Substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)
    Campo, Gianluca
    Tebaldi, Matteo
    Vranckx, Pascal
    Biscaglia, Simone
    Tumscitz, Carlo
    Ferrari, Roberto
    Valgimigli, Marco
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (06) : 506 - 512
  • [27] Optical Coherence Tomography or Intravascular Ultrasound for Complex PCI Different Approaches, Similar Outcomes
    Capodanno, Davide
    Spagnolo, Marco
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (03) : 414 - 416
  • [28] Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis
    Cassese, Salvatore
    Ndrepepa, Gjin
    Kufner, Sebastian
    Byrne, Robert A.
    Giacoppo, Daniele
    Ott, Ilka
    Laugwitz, Karl-Ludwig
    Schunker, Heribert
    Kastrati, Adnan
    Fusaro, Massimiliano
    [J]. EUROINTERVENTION, 2017, 13 (04) : 483 - 489
  • [29] Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting
    Cassese, Salvatore
    Byrne, Robert A.
    Schulz, Stephanie
    Hoppman, Petra
    Kreutzer, Johanna
    Feuchtenberger, Antonia
    Ibrahim, Tareq
    Ott, Ilka
    Fusaro, Massimiliano
    Schunkert, Heribert
    Laugwitz, Karl-Ludwig
    Kastrati, Adnan
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (02) : 94 - 99
  • [30] Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis The RESTORE ISR China Randomized Trial
    Chen, Yundai
    Gao, Lei
    Qin, Qin
    Chen, Shaoliang
    Zhang, Jun
    Chen, Hui
    Wang, Lefeng
    Jin, Zening
    Zheng, Yang
    Zhang, Zheng
    Li, Hui
    Li, Xue
    Fu, Guosheng
    Chen, Lian
    Sun, Zhijun
    Wang, Yu
    Jin, Qinhua
    Cao, Feng
    Guo, Jun
    Zhao, Yanyan
    Guan, Changdong
    Li, Wei
    Xu, Bo
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (23) : 2368 - 2377